DURGA-4
Research type
Research Study
Full title
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4).
IRAS ID
1013000
Contact name
Assim Khan
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
This is a research study funded by AstraZeneca AB. Researchers are looking for a better way to treat multiple myeloma (MM). This cancer affects a type of white blood cells called plasma cells in the bone marrow. Approved treatments slow or stop the progression of MM, but patients’ cancer usually comes back. The cancer is then referred to as relapsed or refractory multiple myeloma (RRMM).
The trial drug AZD0120 is a treatment called chimeric antigen receptor T-cell (CAR-T) therapy. In CAR-T therapy, a sample of a patient’s immune cells is taken from their blood. Researchers then make genetic changes to these cells so they can better identify and kill MM cells. The changed immune cells are given back to the patient through a needle into a vein. A possible benefit of receiving AZD0120 is the improvement of a participant’s cancer.
Participants may be asked to join a follow-up study to be monitored, if they have received AZD0120.
To join this trial, people must be at least 18 years old and have RRMM. People cannot join the trial if they have certain medical conditions that would make it too difficult or risky to participate. The trial will be conducted by hospitals in the UK and in other countries.
Participants will receive either AZD0120 or a standard treatment combination for RRMM.
For the participants assigned to receive AZD0120, doctors will collect blood cells to make AZD0120.
The standard treatment will be given as injections just under the skin, as tablets or capsules taken by mouth, or through a needle directly into a vein (IV infusion), until they no longer receive benefit.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
25/SC/0373
Date of REC Opinion
18 Feb 2026
REC opinion
Further Information Favourable Opinion